Details
Stereochemistry | ACHIRAL |
Molecular Formula | C24H31N3O2S |
Molecular Weight | 425.587 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC(=O)C1=CC2=C(SC3=C(C=CC=C3)N2CCCN4CCN(CCO)CC4)C=C1
InChI
InChIKey=XZSMZRXAEFNJCU-UHFFFAOYSA-N
InChI=1S/C24H31N3O2S/c1-2-22(29)19-8-9-24-21(18-19)27(20-6-3-4-7-23(20)30-24)11-5-10-25-12-14-26(15-13-25)16-17-28/h3-4,6-9,18,28H,2,5,10-17H2,1H3
DescriptionSources: http://www.tabletwise.com/us/proketazine-tabletCurator's Comment: description was created based on several sources, including:
http://edudrugs.com/P/Proketazine/more.html | https://en.wikipedia.org/wiki/Carfenazine | https://www.ncbi.nlm.nih.gov/pubmed/14267601
Sources: http://www.tabletwise.com/us/proketazine-tablet
Curator's Comment: description was created based on several sources, including:
http://edudrugs.com/P/Proketazine/more.html | https://en.wikipedia.org/wiki/Carfenazine | https://www.ncbi.nlm.nih.gov/pubmed/14267601
Carfenazine (brand name Proketazine) is an antipsychotic and tranquilizer of the phenothiazine group. It is used in the treatment of acute or chronic schizophrenic reactions in hospitalized patients. Proketazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis. The following is a list of possible side effects that may occur from all constituting ingredients of Proketazine: akathisia, tardive dyskinesia, extrapyramidal symptoms, allergic purpura.
CNS Activity
Originator
Approval Year
Doses
Dose | Population | Adverse events |
---|---|---|
100 mg 4 times / day steady, oral Dose: 100 mg, 4 times / day Route: oral Route: steady Dose: 100 mg, 4 times / day Sources: |
unhealthy, 18 - 60 years n = 28 Health Status: unhealthy Condition: acutely psychotic Age Group: 18 - 60 years Sex: F Population Size: 28 Sources: |
Disc. AE: Skin rash... Other AEs: Faintness... AEs leading to discontinuation/dose reduction: Skin rash (grade 4, 1 patient) Other AEs:Faintness (1 patient) Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Faintness | 1 patient | 100 mg 4 times / day steady, oral Dose: 100 mg, 4 times / day Route: oral Route: steady Dose: 100 mg, 4 times / day Sources: |
unhealthy, 18 - 60 years n = 28 Health Status: unhealthy Condition: acutely psychotic Age Group: 18 - 60 years Sex: F Population Size: 28 Sources: |
Skin rash | grade 4, 1 patient Disc. AE |
100 mg 4 times / day steady, oral Dose: 100 mg, 4 times / day Route: oral Route: steady Dose: 100 mg, 4 times / day Sources: |
unhealthy, 18 - 60 years n = 28 Health Status: unhealthy Condition: acutely psychotic Age Group: 18 - 60 years Sex: F Population Size: 28 Sources: |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14218188
First week, 25 mg. t.i.d.; second week, 50 mg. t.i.d.; third week, 75 mg. t.i.d.; fourth week, 100 mg. t.i.d.; fifth week and thereafter, 100 mg. q.i.d.
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29710
Created by
admin on Sat Dec 16 16:49:52 GMT 2023 , Edited by admin on Sat Dec 16 16:49:52 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
2622-30-2
Created by
admin on Sat Dec 16 16:49:52 GMT 2023 , Edited by admin on Sat Dec 16 16:49:52 GMT 2023
|
PRIMARY | |||
|
516
Created by
admin on Sat Dec 16 16:49:52 GMT 2023 , Edited by admin on Sat Dec 16 16:49:52 GMT 2023
|
PRIMARY | |||
|
DB01038
Created by
admin on Sat Dec 16 16:49:52 GMT 2023 , Edited by admin on Sat Dec 16 16:49:52 GMT 2023
|
PRIMARY | |||
|
C73285
Created by
admin on Sat Dec 16 16:49:52 GMT 2023 , Edited by admin on Sat Dec 16 16:49:52 GMT 2023
|
PRIMARY | |||
|
m1057
Created by
admin on Sat Dec 16 16:49:52 GMT 2023 , Edited by admin on Sat Dec 16 16:49:52 GMT 2023
|
PRIMARY | Merck Index | ||
|
220-072-9
Created by
admin on Sat Dec 16 16:49:52 GMT 2023 , Edited by admin on Sat Dec 16 16:49:52 GMT 2023
|
PRIMARY | |||
|
CLY16Y8Z7E
Created by
admin on Sat Dec 16 16:49:52 GMT 2023 , Edited by admin on Sat Dec 16 16:49:52 GMT 2023
|
PRIMARY | |||
|
51235
Created by
admin on Sat Dec 16 16:49:52 GMT 2023 , Edited by admin on Sat Dec 16 16:49:52 GMT 2023
|
PRIMARY | |||
|
Carfenazine
Created by
admin on Sat Dec 16 16:49:52 GMT 2023 , Edited by admin on Sat Dec 16 16:49:52 GMT 2023
|
PRIMARY | |||
|
CHEMBL1201328
Created by
admin on Sat Dec 16 16:49:52 GMT 2023 , Edited by admin on Sat Dec 16 16:49:52 GMT 2023
|
PRIMARY | |||
|
7140
Created by
admin on Sat Dec 16 16:49:52 GMT 2023 , Edited by admin on Sat Dec 16 16:49:52 GMT 2023
|
PRIMARY | |||
|
DTXSID8022745
Created by
admin on Sat Dec 16 16:49:52 GMT 2023 , Edited by admin on Sat Dec 16 16:49:52 GMT 2023
|
PRIMARY | |||
|
1179
Created by
admin on Sat Dec 16 16:49:52 GMT 2023 , Edited by admin on Sat Dec 16 16:49:52 GMT 2023
|
PRIMARY | |||
|
18104
Created by
admin on Sat Dec 16 16:49:52 GMT 2023 , Edited by admin on Sat Dec 16 16:49:52 GMT 2023
|
PRIMARY | |||
|
100000084572
Created by
admin on Sat Dec 16 16:49:52 GMT 2023 , Edited by admin on Sat Dec 16 16:49:52 GMT 2023
|
PRIMARY | |||
|
SUB06625MIG
Created by
admin on Sat Dec 16 16:49:52 GMT 2023 , Edited by admin on Sat Dec 16 16:49:52 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)